Relx (NYSE:RELX) Reaches New 1-Year High – Still a Buy?

Relx Plc (NYSE:RELX)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $51.09 and last traded at $51.01, with a volume of 34952 shares. The stock had previously closed at $50.56.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Redburn Atlantic initiated coverage on Relx in a report on Wednesday, January 8th. They set a “buy” rating for the company. StockNews.com began coverage on shares of Relx in a research note on Wednesday, October 30th. They set a “hold” rating for the company.

Relx Stock Performance

The firm has a 50-day simple moving average of $47.66 and a two-hundred day simple moving average of $47.09. The company has a debt-to-equity ratio of 1.63, a quick ratio of 0.42 and a current ratio of 0.48.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Raymond James Financial Inc. purchased a new stake in Relx in the 4th quarter worth approximately $44,516,000. Arrowstreet Capital Limited Partnership lifted its stake in shares of Relx by 50.3% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,968,739 shares of the technology company’s stock valued at $89,420,000 after purchasing an additional 658,655 shares during the period. FMR LLC boosted its holdings in Relx by 8.3% during the third quarter. FMR LLC now owns 7,148,837 shares of the technology company’s stock worth $339,284,000 after buying an additional 548,423 shares in the last quarter. Mediolanum International Funds Ltd acquired a new stake in Relx during the third quarter valued at $12,902,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Relx during the fourth quarter valued at $9,920,000. 15.02% of the stock is currently owned by hedge funds and other institutional investors.

About Relx

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.